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In vivo transplantation into the mammary fat pad 
represents the cornerstone assay for evaluating mammary 
stem cell (MaSC) activity. Pioneering work has shown 
that mammary epithelial outgrowths can be generated in 
de-epithelialized (or cleared) fat pads transplanted with 
explants or admixtures of mammary cells [1]. More 
recently, MaSCs have been prospectively isolated and 
demonstrated to exhibit multilineage diﬀ  erentiation and 
self-renewal properties through the transplantation of 
limiting numbers of empirically derived cell sub  popu-
lations. A MaSC-enriched basal population was identiﬁ  ed 
on the basis of high expression of integrin β1 (CD29) or 
integrin α6 (CD49f) and moderate levels of CD24 [2,3], 
with an estimated stem cell frequency of 1 in 60. Using 
CD24 as a single marker, the CD24mod subset was shown 
to comprise almost all repopulating activity [4,5].
A number of recent studies have incorporated the re-
constituted extracellular matrix Matrigel (BD Biosciences) 
in their mammary transplantation assays, with a view to 
creating an improved microenvironment for the implan-
tation of stem cells. Th  ese studies have included the 
transplantation of unsorted mammary cells, in which as 
few as 100 cells could reconstitute an entire mammary 
gland [6], and the transplantation of sorted epithelial sub-
populations embedded in Matrigel [7-10]. Interestingly, 
Matrigel was recently shown to enhance melanoma cell 
tumor-initiating capacity several-fold [11]. Given the 
increasing use of Matrigel in transplantation assays, we 
have directly assessed the eﬀ  ect of this matrix on the 
repopulating capacity of two distinct subpopu  lations 
isolated from normal mouse mammary glands: the 
MaSC-enriched subset and the luminal cell subset, the 
latter of which comprises committed luminal progenitor 
and mature luminal cells. We report here that the luminal 
sub  popu  lation can yield limited ductal out  growths, but 
only in the presence of Matrigel. Th  ese data raise the 
possibility that rare bipotent cells in this subset are 
activated by matrix components or that committed 
luminal progenitor cells can undergo dediﬀ  erentiation. In 
either case, these cells do not represent true MaSCs.
MaSCs have previously been shown to lie within the 
CD29hi (or CD49fhi) CD24+ population, while extensive 
transplantation assays of luminal cell fractions including 
the CD61+ luminal progenitor subset have demonstrated 
that this luminal population lacks repopulating potential 
[2,3,12]. In human breast tissue, stem cell activity was 
similarly demonstrated to occur in the basal population 
[13,14]. To address the inﬂ  uence of Matrigel on in vivo
mammary repopulating capacity, we transplanted double-
sorted cells from the MaSC-enriched subset (CD29hiCD24+) 
and the luminal subset (CD29loCD24+) in either 0%, 25% 
or 50% Matrigel. Donor cells were derived from Rosa26 
mice to allow deﬁ  nitive identiﬁ  cation of outgrowths from 
implanted cells by virtue of β-galactosidase activity. Cells 
within the CD29hiCD24+  subset were transplanted at 
limiting dilution, in which 1 in 75 cells is estimated to be 
a MaSC [2], while an excess of luminal cells (1,000 cells) 
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© 2011 BioMed Central Ltdwere injected. Matrigel at both concentrations was found 
to substantially enhance the mammary repopulating 
frequency of the MaSC-enriched subpopulation, with the 
percentage of outgrowths from transplanted cells almost 
doubling in the presence of 50% Matrigel compared with 
no Matrigel (Figure 1). In general, more extensive ﬁ  lling 
of the fat pad was apparent in the presence of this matrix. 
Th  ese data are compatible with the increased engraft-
ment observed upon inclusion of 50% Matrigel [9]. 
Constituents within Matrigel may enhance the viability 
and/or activity of stem cells, resulting in increased 
repopulating capacity.
Unexpectedly, transplantation of the luminal subpopu-
lation in Matrigel gave rise to small branched structures 
(Figure 1a,b): 10.7% and 22.5% were observed in the 
presence of 25% and 50% Matrigel, respectively. No out-
growths, however, were generated from this subpopu-
lation in the absence of Matrigel, consistent with previous 
studies [2,3]. Notably, only diminutive outgrowths arose 
from luminal subset cells inoculated in 50% Matrigel, 
although each structure exhibited ductal branching from 
a central point and was therefore scored (Figure 1b,c). In 
the case of 25% Matrigel, the structures ﬁ  lled approxi-
mately 1% of the fat pad.
Figure 1. Eff  ect of Matrigel on the transplantation of mammary epithelial cell subpopulations. (a) Table showing the number of outgrowths 
per number of mammary fad pads injected with either 75 CD29hiCD24+ (mammary stem cell (MaSC)-enriched) cells or 1,000 CD29loCD24+ 
(luminal) cells, in either 0%, 25% or 50% Matrigel. Single cell suspensions were prepared from the mammary glands of 8-week-old to 10-week-old 
FVB/N-Rosa26 female mice, labeled with fl  uorochrome-conjugated antibodies and double-sorted as described [2]. The MaSC-enriched and luminal 
cell populations were identifi  ed following depletion of endothelial and hematopoietic cells using anti-CD45, anti-CD31 and anti-TER119 antibodies. 
Cells were injected (10 μl volume) into the cleared inguinal mammary fat pads of 3-week-old FVB/N female recipients and were collected 8 
weeks post transplantation for X-gal staining. β-Gal+ branched ductal structures were scored as positive. Data are shown for four independent 
experiments. (b) Images of X-gal-stained outgrowths: outgrowth derived from transplantation of 75 CD29hiCD24+ cells in 50% Matrigel (top), and 
largest outgrowth obtained from transplantation of 1,000 CD29loCD24+ cells in 50% Matrigel (bottom). Bar = 1 mm. (c) Bar chart representation 
of mammary outgrowths as a function of fat-pad fi  lling following transplantation of each subpopulation. The axes shown diff  er for the two 
populations, since very few structures were generated by the CD29loCD24+ population and these did not exceed 5%. Data are shown for four 
independent experiments. MFP, mammary fat pad.
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Page 2 of 4Secondary transplantation experiments were carried 
out from luminal cell-derived (n = 3) or MaSC-derived 
(n  =  3) outgrowths to determine whether the luminal 
cell-derived outgrowths contained cells with self-renewal 
capacity. No outgrowths were present in 20 recipient 
glands, whereas prominent ductal outgrowths were 
evident in recipient glands from all three MaSC-derived 
outgrowths (15/20). Th   us the Matrigel-associated luminal 
cell-derived (CD29loCD24+) outgrowths did not exhibit 
self-renewal properties, a hallmark feature of stem cells.
Contamination of this luminal subpopulation (double-
sorted and purity conﬁ  rmed by reanalysis) with MaSCs 
seems unlikely as no outgrowths were evident in the 
absence of Matrigel, and no extensive outgrowths were 
ever observed. Rather, Matrigel may be providing a 
micro  environment that activates rare bipotent progenitor 
cells capable of regeneration, albeit limited. Alternatively, 
luminal progenitor cells within this subpopulation may 
occasion  ally adopt a more primitive state. Th  ese data 
diﬀ  er from those recently reported in which Matrigel was 
found to be necessary for the generation of outgrowths 
from both the CD49fhiCD24med and CD49floCD24hi 
subpopulations [10]. Contrary to the ﬁ  ndings described 
here, a similar degree of engraftment was noted for each 
population, perhaps reﬂ  ecting the large number of cells 
transplanted (50,000 cells) [10].
It is conceivable that the activation of signaling path-
ways by Matrigel components can stimulate certain cells 
to acquire a more primitive state. Matrigel is a solubilized 
basement membrane extracted from Engelbreth–Holm–
Swarm mouse sarcoma and is rich in laminin, collagen 
IV, proteoglycans as well as a number of diﬀ  erent growth 
factors [15]. Th  e nature of the substance or growth 
factors in Matrigel that may confer a more permissive 
environment for progenitor activity is yet to be 
determined. Growth factor-reduced Matrigel could be 
considered an alternative to complete Matrigel to 
perhaps distinguish eﬀ  ects of the substratum components 
from those of growth factors on mammary reconstitution.
Matrigel has been widely used to study tumor cell 
invasion, and an altered extracellular matrix has been 
shown to promote tumorigenesis [16]. In xenotrans  plan-
tation assays to identify cancer stem cells in primary 
tumors, it is pertinent that only the cancer stem cell 
fraction and not the negative fraction had tumor-
initiating capacity in mice when inoculated in Matrigel 
[17]. Th  is reconstituted basement membrane, however, 
has been found to facilitate tumorigenesis of human 
breast cancers, squamous cell carcinomas and teratomas 
in mice [18-20], suggesting it has the potential to provide 
tumor cells with additional survival and/or proliferative 
signals. Th  e  inﬂ  uence of Matrigel on established tumors, 
however, is a distinct question from its impact on normal 
cells.
In summary, our data suggest that, in addition to 
increasing the rate of engraftment by MaSCs, Matrigel 
appears to promote progenitor activity in the luminal 
subset that is not seen in its absence. It is important to 
note that these cells with limited regenerative potential 
are distinct from bona ﬁ  de MaSCs that lie within the 
basal population and should not be scored as such. A 
degree of caution should thus be applied to interpreting 
data from mammary cell transplantation experiments 
that incorporate Matrigel, particularly when trans  plant-
ing high cell numbers. Additional studies (such as com-
parison of complete Matrigel and growth factor-reduced 
Matrigel) will be required to resolve the question of 
whether it is more or less physiological to include this 
matrix in transplantation assays for MaSC function.
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